Showing results (51-60 of 69) with videos related to
Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|March 6, 2019
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to HumansJürgen B Bulitta, William W Hope, Ann E Eakin, et al.The Journal of Antimicrobial Chemotherapy|May 31, 2015
Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactamRenu Singh, Aryun Kim, M Angela Tanudra, et al.Protein Science : a Publication of the Protein Society|May 25, 1999
Ternary complex structure of human HGPRTase, PRPP, Mg2+, and the inhibitor HPP reveals the involvement of the flexible loop in substrate bindingG K Balendiran, J A Molina, Y Xu, et al.Journal of Medicinal Chemistry|October 9, 2013
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agentsGregory S Basarab, John I Manchester, Shanta Bist, et al.Viruses|December 28, 2021
SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic ActivitySabari Nath Neerukonda, Russell Vassell, Sabrina Lusvarghi, et al.Biorxiv : the Preprint Server for Biology|November 18, 2021
SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activitySabari Nath Neerukonda, Russell Vassell, Sabrina Lusvarghi, et al.Antimicrobial Agents and Chemotherapy|March 6, 2019
Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial AgentsM L Rizk, S M Bhavnani, G Drusano, et al.Antimicrobial Agents and Chemotherapy|December 30, 2010
Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivoScott D Mills, Ann E Eakin, Ed T Buurman, et al.The Journal of Antimicrobial Chemotherapy|May 29, 2020
Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection modelThomas P Lodise, Nicolas M Smith, Nick O'Donnell, et al.Bioorganic & Medicinal Chemistry Letters|November 2, 2011
Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacyBrian A Sherer, Kenneth Hull, Oluyinka Green, et al.Pageof 7